Intravenous Infusion of Autologous Mesenchymal Stem Cells Expanded in Auto Serum for Chronic Spinal Cord Injury Patients: A Case Series
Ryosuke Hirota,Masanori Sasaki,Satoshi Iyama,Kota Kurihara,Ryunosuke Fukushi,Hisashi Obara,Tsutomu Oshigiri,Tomonori Morita,Masahito Nakazaki,Takahiro Namioka,Ai Namioka,Rie Onodera,Yuko Kataoka-Sasaki,Shinichi Oka,Mitsuhiro Takemura,Ryo Ukai,Takahiro Yokoyama,Yuichi Sasaki,Tatsuro Yamashita,Masato Kobayashi,Yusuke Okuma,Reiko Kondo,Ryo Aichi,Satoko Ohmatsu,Noritaka Kawashima,Yoichi M Ito,Masayoshi Kobune,Kohichi Takada,Sumio Ishiai,Toru Ogata,Atsushi Teramoto,Toshihiko Yamashita,Jeffery D Kocsis,Osamu Honmou
DOI: https://doi.org/10.3390/jcm13206072
2024-10-11
Abstract:Objective: The safety, feasibility, and potential functional improvement following the intravenous infusion of mesenchymal stem cells (MSCs) were investigated in patients with chronic severe spinal cord injury (SCI). Methods: The intravenous infusion of autologous MSCs cultured in auto-serum under Good Manufacturing Practices (GMP) was administered to seven patients with chronic SCI (ranging from 1.3 years to 27 years after the onset of SCI). In addition to evaluating feasibility and safety, neurological function was evaluated using the American Spinal Injury Association Impairment Scale (AIS), International Standards for Neurological Classification of Spinal Cord Injury (ISCSCI-92), and Spinal Cord Independence Measure III (SCIM-III). Results: No serious adverse events occurred. Neither CNS tumors, abnormal cell growth, nor neurological deterioration occurred in any patients. While this initial case series was not blinded, significant functional improvements and increased quality of life (QOL) were observed at 90 and 180 days post-MSC infusion compared to pre-infusion status. One patient who had an AIS grade C improved to grade D within six months after MSC infusion. Conclusions: This case series suggests that the intravenous infusion of autologous MSCs is a safe and feasible therapeutic approach for chronic SCI patients. Furthermore, our data showed significant functional improvements and better QOL after MSC infusion in patients with chronic SCI. A blind large-scale study will be necessary to fully evaluate this possibility.